HYPERHIDROSISNCT01810991
Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
A study testing Nd:YAG Laser in people with HYPERHIDROSIS, run by Cynosure, Inc. at 1 site in United States.
Trial summary
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- HYPERHIDROSIS
- What is being tested?
- Nd:YAG Laser
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2012to Apr 2014
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A healthy non-smoking male or female between 18-56 years of age
- Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment
- Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits
- Clinically diagnosed for primary hyperhidrosis of the axilla.
- A self assessed Hyperhidrosis Disease Severity Scale (HDSS) score of three (3) or four (4)
Who cannot join
- Clinical diagnosis of secondary hyperhidrosis
- Uncontrolled systemic disease
- Concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants
- Receipt of Botox or Dysport within the past six months
- Patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that Minors starch iodine tests may be performed.
- Patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except over the counter antiperspirant or planning to use such agents during the course of the study.
Show all 18Show fewer
- Any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; OR any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months or planning to have any treatments for hyperhidrosis or surgery within the treatment area during the course of the study.
- Allergies to medication or local anesthesia required for the procedure
- A history of thrombophlebitis
- A history of acute infections
- A history of heart failure
- Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E or anti inflammatories within 2 weeks pre treatment
- An intolerance to anesthesia
- Any medical condition, that, in the investigator's opinion would interfere with the patient's participation in the study
- Taking medications that are photosensitive
- A history of keloid formation
- Is pregnant or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the course of the study
- Study subjects that can not maintain their pre-study exercise and diet routine over the course of the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Juva Skin and Laser Center
New York, New York, 10021
About this study
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Conditions
- HYPERHIDROSIS
- Being tested
- Nd:YAG Laser
- Medical subject headings
- Hyperhidrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nd:YAG LaserDevice
Nd:YAG 1440nm Laser
| Study group | Role | What they receive |
|---|---|---|
| Nd:YAG Laser | Experimental | Nd:YAG 1440nm Laser Receives: Device: Nd:YAG Laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Photographs Identified Accurately
3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.
Measured: 3 Month Follow Up
Percentage of Photographs Identified Accurately
3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.
Measured: 6 Month Follow Up
Secondary outcomes (1)
Number of Participants With Changed and Unchanged Glands on Biopsy Sampling
Hematoxylin and eosin (H\&E) staining was performed on all pre and post treatment biopsy samples and evaluated by a pathologist to determine if there was any change in the subjects' glands at baseline vs. post last treatment. Changes in glands are characterized by reduction in quantity and size, in addition to changes in shape.
Measured: up to 3 months post last treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2013 (estimated)
- Study startJun 2012
- Primary completionApr 2014
- Study completionApr 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HYPERHIDROSISStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cynosure, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Patricia Krantz, Study director, Cynosure, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01810991
- Sponsor's protocol ID
- CYN12-1440-BK-HID1
- Status last verified
- Feb 2021
- First submitted
- 6 Dec 2012
- Last updated
- 4 Mar 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
- ClinicalTrials.gov ID
- NCT01810991
- Acronym / sponsor ID
- CYN12-1440-BK-HID1
- Conditions
- HYPERHIDROSIS
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Cynosure, Inc.Industry (pharma, biotech, devices)
- Study start
- Jun 2012
- Primary completion
- Apr 2014 (actual)
- Study completion
- Apr 2014 (actual)
- First posted
- 14 Mar 2013 (estimated)
- Results
- Posted 10 Dec 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Nd:YAG Laser | Experimental | Device: Nd:YAG LaserNd:YAG 1440nm Laser |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- A healthy non-smoking male or female between 18-56 years of age
- Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment
- Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits
- Clinically diagnosed for primary hyperhidrosis of the axilla.
- A self assessed Hyperhidrosis Disease Severity Scale (HDSS) score of three (3) or four (4)
Key exclusion criteria (18 listed)
- Clinical diagnosis of secondary hyperhidrosis
- Uncontrolled systemic disease
- Concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants
- Receipt of Botox or Dysport within the past six months
- Patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that Minors starch iodine tests may be performed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nd:YAG LaserNd:YAG 1440nm Laser | Device | Nd:YAG Laser |
Primary outcome
Percentage of Photographs Identified Accurately
Time frame: 3 Month Follow Up
3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.
Percentage of Photographs Identified Accurately
Time frame: 6 Month Follow Up
3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.
1 secondary outcome
Number of Participants With Changed and Unchanged Glands on Biopsy Sampling
Time frame: up to 3 months post last treatment
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for HYPERHIDROSIS
RecruitingObservational study
Targeting Nociceptors in Hidradenitis Suppurativa
Hidradenitis Suppurativa, Hyperhidrosis
Not yet recruiting
20% Alcohol With Steroid Local Anesthetic Technique Versus Steroid Local Anesthetic Technique Only in Stellate Ganglion Injection in Idiopathic Palmar Hyperhydrosis
Hyperhidrosis
Recruiting
Botulinum Toxin Type A for Frontal Hyperhidrosis
Primary Frontal Hyperhidrosis
Not yet recruitingObservational study
"Incidence of Compensatory Hyperhidrosis After T3 Vs T3-4 Sympathectomy"
Compensatory Hyperhidrosis, Compensatory Sweating
Recruiting
A Polymer Film Device to Treat Excessive Palmar Sweating
Palmar Hyperhidrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricia Krantz study director
Cynosure, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nd:YAG Laser in people with HYPERHIDROSIS, run by Cynosure, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Dec 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Photographs Identified Accurately (time frame: 3 Month Follow Up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2021.